Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Bemarituzumab/Chemo Combo Translates to OS Advantage in FGFR2b+ Gastric/GEJ Cancer

October 20th 2025

Bemarituzumab/mFOLFOX6 produced an OS advantage over placebo/mFOLFOX6 in FGFR2b-overexpressing gastric/GEJ cancer; this was attenuated at longer follow-up.

FDA Awards Breakthrough Therapy Designation to Bezuclastinib for Non-Advanced Systemic Mastocytosis

October 20th 2025

Bezuclastinib received breakthrough therapy designation for pretreated non-advanced systemic mastocytosis, as well as for smoldering systemic mastocytosis.

FDA Accepts BLA Resubmission for RP1 Plus Nivolumab in Advanced Melanoma

October 20th 2025

Will the FDA approve a resubmitted biologics license application for RP1 plus nivolumab in advanced melanoma after progression on anti–PD-1 therapy?

Tislelizumab Plus Chemo/Concurrent Chemoradiotherapy Yields Survival Advantage in Locally Advanced ESCC

October 19th 2025

Tislelizumab plus induction chemotherapy and concurrent chemoradiation demonstrated efficacy worthy of further study in locally advanced ESCC.

Chemotherapy Plus Durvalumab, Bevacizumab, and Olaparib Fails to Offer OS Benefit in Newly Diagnosed Non-tBRCA–Mutated Ovarian Cancer

October 19th 2025

Chemotherapy plus durvalumab, bevacizumab, and olaparib did not significantly prolong OS in non-tBRCA-mutated ovarian cancer.

Relacorilant Plus Nab-Paclitaxel Yields PFS Advantage in PARP Inhibitor–Exposed PROC

October 19th 2025

The addition of relacorilant to nab-paclitaxel produced a PFS benefit vs nab-paclitaxel alone in PROC with a history of PARP inhibitor exposure.

Perioperative Enfortumab Vedotin Plus Pembrolizumab May Represent New SOC in Cisplatin-Ineligible MIBC

October 18th 2025

Enfortumab vedotin plus pembrolizumab significantly improved survival and pCR vs surgery alone in cisplatin-ineligible MIBC per KEYNOTE-905 data.

Adjuvant Nivolumab Displays Long-Term Activity in Resected Melanoma

October 18th 2025

Adjuvant nivolumab significantly extended RFS vs ipilimumab in patients with resected stage IIIB to IIIC or IV melanoma.

T-DXd Improves IDFS and DFS vs T-DM1 in HER2+ Breast Cancer With Residual Invasive Disease

October 18th 2025

T-DXd significantly improved IDFS vs T-DM1 in high-risk, HER2-positive primary breast cancer with residual invasive disease after neoadjuvant therapy.

Long-Term MANEUVER Trial Data Spotlight Durable Responses With Pimicotinib in TGCT

October 17th 2025

Long-term data demonstrated durable responses with pimicotinib in tenosynovial giant cell tumor.

Adjuvant Ribociclib Plus AI Therapy Has Long-Term Activity in HR+, HER2-Negative Early Breast Cancer

October 17th 2025

Adjuvant ribociclib plus an aromatase inhibitor was safe and displayed long-term efficacy in hormone receptor–positive, HER2-negative early breast cancer.

Abemaciclib Plus Endocrine Therapy Provides OS Benefit in HR+/HER2-Negative Breast Cancer

October 17th 2025

The addition of adjuvant abemaciclib to endocrine therapy provided an OS benefit vs endocrine therapy alone in hormone receptor–positive breast cancer.

FDA Approval Insights: Subcutaneous Pembrolizumab for Solid Tumors: With J. Thaddeus Beck, MD, FACP

October 16th 2025

J. Thaddeus Beck, MD, FACP, about the FDA approval of subcutaneous pembrolizumab.

Axi-Cel Advances Signal Shifts Toward Earlier-Line Applications in LBCL

October 16th 2025

Taylor Brooks, MD, discusses the effects of CAR T-cell therapy on LBCL management and the efficacy of axi-cel for patients with relapsed/refractory LBCL.

Dr Visco on the Design of the FIL_V-RBAC Trial of RBAC Plus Venetoclax in High-Risk MCL

October 16th 2025

Carlo Visco, MD, discussed key design elements of the FIL_V-RBAC study of RBAC followed by venetoclax in older patients with high-risk MCL.

Dr O’Shaughnessy on Highly Anticipated Breast Cancer Data to Watch at ESMO 2025

October 16th 2025

Joyce A. O’Shaughnessy, MD, highlights the breast cancer data being presented at ESMO 2025 that have the greatest potential to shape clinical practice.

JAK Inhibitors Persist, While Novel Agents Aim for Disease Modification in Myelofibrosis

October 16th 2025

Aaron Gerds, MD, MS, discusses the clinical applications of each of the FDA-approved JAK inhibitors for the treatment of patients with myelofibrosis.

Study Shows ChatGPT Struggles With Patient-Specific Queries, Novel Therapies in Hematologic Malignancies

October 16th 2025

A study found ChatGPT 3.5 was more likely to give incomplete or inaccurate answers to specific hematologic malignancy queries vs general questions.

Dr Tarantino on the Role of Genomic Testing in HER2+ Breast Cancer

October 16th 2025

Paolo Tarantino, MD, PhD, discusses the role of genomic testing for guiding treatment decisions for patients with HER2-positive breast cancer.

Dr Randall on the Diagnostic Accuracy and Cost Effectiveness of MRI vs Ultrasound in STS

October 16th 2025

R. Lor Randall, MD, FACS, compares the diagnostic accuracy, recurrence detection rates, and cost effectiveness of MRI vs ultrasound STS surveillance.